View source for 17767857. ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)

=ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF=


==Organization Name==

[[:Category:Arizona Board of Regents on Behalf of Arizona State University|Arizona Board of Regents on Behalf of Arizona State University]]


[[Category:Arizona Board of Regents on Behalf of Arizona State University]]

==Inventor(s)==

[[:Category:Douglas Grant Mcfadden of Tempe AZ (US)|Douglas Grant Mcfadden of Tempe AZ (US)]][[Category:Douglas Grant Mcfadden of Tempe AZ (US)]]

[[:Category:Lino Torres-dominguez of Tempe AZ (US)|Lino Torres-dominguez of Tempe AZ (US)]][[Category:Lino Torres-dominguez of Tempe AZ (US)]]

[[:Category:Nancy Villa of Tempe AZ (US)|Nancy Villa of Tempe AZ (US)]][[Category:Nancy Villa of Tempe AZ (US)]]

[[:Category:Mohammed Masmudur Rahman of Chandler AZ (US)|Mohammed Masmudur Rahman of Chandler AZ (US)]][[Category:Mohammed Masmudur Rahman of Chandler AZ (US)]]

==ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF - A simplified explanation of the abstract==


This abstract first appeared for US patent application 17767857 titled 'ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF

==Simplified Explanation==

The patent application describes a Myxoma virus that expresses immunomodulatory transgenes for inhibiting and treating hematological cancer in a subject, as well as the use of leukocytes containing this virus for the same purpose.

* Myxoma virus engineered to express immunomodulatory transgenes
* Use of virus-infected leukocytes to treat hematological cancer

== Potential Applications ==
The technology could be applied in the treatment of various types of hematological cancers, such as leukemia, lymphoma, and myeloma.

== Problems Solved ==
This technology addresses the challenge of effectively targeting and treating hematological cancers, which can be difficult to treat with traditional methods.

== Benefits ==
- Enhanced immune response against cancer cells
- Targeted delivery of immunomodulatory agents to the tumor site
- Potential for personalized treatment approaches

== Potential Commercial Applications ==
"Enhancing Hematological Cancer Treatment with Myxoma Virus-Infected Leukocytes"

== Possible Prior Art ==
There have been previous studies on using oncolytic viruses for cancer treatment, but the specific combination of Myxoma virus and immunomodulatory transgenes for hematological cancers may be novel.

== Unanswered Questions ==
=== What are the potential side effects of using Myxoma virus-infected leukocytes for cancer treatment? ===
The article does not delve into the possible adverse effects that may arise from this treatment approach.

=== How does the immune system respond to the presence of Myxoma virus-infected leukocytes in the body? ===
The immune response to the engineered virus-infected leukocytes is not discussed in detail in the article.


==Original Abstract Submitted==

The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.



[[Category:A61K35/768]]
[[Category:A61K35/15]]
[[Category:A61P33/00]]